Medical School, The University of Western Australia, Perth, Australia.
Cancer Research And Biostatistics, Seattle, Washington.
J Thorac Oncol. 2024 Sep;19(9):1339-1351. doi: 10.1016/j.jtho.2024.05.002. Epub 2024 May 9.
The eighth edition of the TNM classification of pleural mesothelioma (PM) saw substantial changes in T and N components and stage groupings. The International Association for the Study of Lung Cancer collected data into a multinational database to further refine this classification. This ninth edition proposal incorporates changes proposed in the clinical (c)T component but not the pathologic T component, to include size criteria, and further refines TNM stage groupings for PM.
Data were submitted through electronic data capture or batch transfer from institutional databases. Survival was measured from diagnosis date. Candidate stage groups were developed using a recursive partitioning and amalgamation algorithm applied to all cM0 cases for clinical stage and subsequently for pathologic stage. Cox models were developed to estimate survival for each stage group.
Of 3598 submitted cases, 2192 were analyzable for overall clinical stage and 445 for overall pathologic stage. Recursive partitioning and amalgamation generated survival tree on overall survival outcomes restricted to cM0, with newly proposed (ninth edition) cT and cN component-derived optimal stage groupings of stage I (T1N0), II (T1N1; T2N0), IIIA (T1N2; T2N1/2; any T3), IIIB (any T4), and IV (any M1). Although cT and pathologic T descriptors are different in the ninth edition, aligning pathologic stage groupings with clinical stage produced better discrimination than did retaining eighth edition pathologic stage groupings.
To our knowledge, this revision of the clinical TNM classification for PM is the first to incorporate the measurement-based proposed changes in cT category. The pathologic TNM aligns with clinical TNM.
第八版胸膜间皮瘤(PM)的 TNM 分类在 T 和 N 成分以及分期分组方面发生了重大变化。国际肺癌研究协会(IASLC)收集了多国数据库的数据,以进一步完善这一分级。本第九版建议纳入了临床(c)T 成分中提出的但未纳入病理 T 成分的变化,包括大小标准,并进一步细化了 PM 的 TNM 分期分组。
数据通过电子数据捕获或从机构数据库的批量传输提交。生存时间从诊断日期开始计算。候选分期组通过递归分区和合并算法应用于所有 cM0 临床分期病例,并随后应用于病理分期病例。开发 Cox 模型来估计每个分期组的生存情况。
在提交的 3598 例病例中,2192 例可用于总体临床分期分析,445 例可用于总体病理分期分析。递归分区和合并生成了生存树,仅限于 cM0,具有新提出的(第九版)cT 和 cN 成分衍生的最佳分期分组:I 期(T1N0)、II 期(T1N1;T2N0)、IIIA 期(T1N2;T2N1/2;任何 T3)、IIIB 期(任何 T4)和 IV 期(任何 M1)。虽然第九版的 cT 和病理 T 描述符不同,但与保留第八版病理分期分组相比,使病理分期分组与临床分期分组一致可提高区分度。
据我们所知,这是首次将基于测量的 cT 类别的提议变更纳入胸膜间皮瘤临床 TNM 分类的修订。病理 TNM 与临床 TNM 一致。